Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia

荆珊,孙宁玲,李小鹰,华琦,王林,李占全,孙英贤,王晓波,苏海

2013-01-01

Abstract:Objective: To evaluate the efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia. Methods: A double-blind randomized multicenter clinical trial was conducted. A total of 344 patients with hypercholesterolemia were randomly divided into three groups: atorvastatin 10 mg·d-1 in 114 patients, rosuvastatin 5 mg·d-1 in 115 patients and rosuvastatin 10 mg·d-1 in 115 patients for 8 weeks. At 4 weeks after treatment, drug dosages were doubled for additional 4 week if the LDL-C levels ≥3.12 mmol·L-1. Results: The TC and LDL-C levels were decreased at 8 weeks in each group (P<0.01). TC decreased from (6.64±0.9) mmol·L-1 to (4.76±0.94) mmol·L-1 in atorvastatin 10 mg·d-1 group; from (6.61±0.75) mmol·L-1 to (4.39±0.90) mmol·L-1 in rosuvastatin 10 mg·d-1 group; from (6.74±0.76)) mmol·L-1 to (4.72±0.87) mmol·L-1 in rosuvastatin 5 mg·d-1 group. LDL-C decreased from (4.40±0.87) mmol·L-1 to (2.62±0.90) mmol·L-1 in atorvastatin 10 mg·d-1 group; from (4.37±0.76) mmol·L-1 to (2.30±0.84) mmol·L-1 in rosuvastatin 10 mg·d-1 group; from (4.48±0.68) mmol·L-1 to (2.58±0.89) mmol·L-1 in rosuvastatin 5 mg·d-1 group. The TC and LDL-C reductions were significantly differed between rosuvastatin 10 mg·d-1 group and atorvastatin 10 mg·d-1 group (P<0.05). Arterial stiffness index was not significantly different among three groups (P>0.05). The adverse reactions were similar in three groups. Conclusion: Rosuvastatin can significantly reduce TC and LDL-C in patients with hypercholesterolemia, and has better safety and tolerance. It can be used in the treatment of hypercholesterolemia.